Chemoradiotherapy in locally advanced bladder carcinoma

Research output: Contribution to journalArticle

Abstract

Bladder carcinoma represents the fifth leading cause of cancer in the United States. For patients with muscle-invasive tumors, radical cystectomy has been the treatment of choice, yet over 50% of such treated patients are destined to develop recurrent disease. In order to minimize morbidity in patients with invasive disease, bladder-sparing techniques using radiotherapy alone, or with chemotherapy, have been investigated. While it is clear that durable complete remission can be achieved in some patients, the results to date require additional follow-up to determine the optimal cohort of patients destined to benefit from this approach. It is hoped that ongoing prospective trials will delineate this population.

Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalSeminars in oncology
Volume19
Issue number4 SUPPL. 11
StatePublished - Aug 1992

Fingerprint

Chemoradiotherapy
Urinary Bladder
Carcinoma
Urinary Bladder Diseases
Cystectomy
Neoplasms
Radiotherapy
Morbidity
Drug Therapy
Muscles
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Chemoradiotherapy in locally advanced bladder carcinoma. / Loehrer, Patrick J.

In: Seminars in oncology, Vol. 19, No. 4 SUPPL. 11, 08.1992, p. 92-95.

Research output: Contribution to journalArticle

@article{eb1ca7f5343648b5bf062cb597b92e8d,
title = "Chemoradiotherapy in locally advanced bladder carcinoma",
abstract = "Bladder carcinoma represents the fifth leading cause of cancer in the United States. For patients with muscle-invasive tumors, radical cystectomy has been the treatment of choice, yet over 50{\%} of such treated patients are destined to develop recurrent disease. In order to minimize morbidity in patients with invasive disease, bladder-sparing techniques using radiotherapy alone, or with chemotherapy, have been investigated. While it is clear that durable complete remission can be achieved in some patients, the results to date require additional follow-up to determine the optimal cohort of patients destined to benefit from this approach. It is hoped that ongoing prospective trials will delineate this population.",
author = "Loehrer, {Patrick J.}",
year = "1992",
month = "8",
language = "English (US)",
volume = "19",
pages = "92--95",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 11",

}

TY - JOUR

T1 - Chemoradiotherapy in locally advanced bladder carcinoma

AU - Loehrer, Patrick J.

PY - 1992/8

Y1 - 1992/8

N2 - Bladder carcinoma represents the fifth leading cause of cancer in the United States. For patients with muscle-invasive tumors, radical cystectomy has been the treatment of choice, yet over 50% of such treated patients are destined to develop recurrent disease. In order to minimize morbidity in patients with invasive disease, bladder-sparing techniques using radiotherapy alone, or with chemotherapy, have been investigated. While it is clear that durable complete remission can be achieved in some patients, the results to date require additional follow-up to determine the optimal cohort of patients destined to benefit from this approach. It is hoped that ongoing prospective trials will delineate this population.

AB - Bladder carcinoma represents the fifth leading cause of cancer in the United States. For patients with muscle-invasive tumors, radical cystectomy has been the treatment of choice, yet over 50% of such treated patients are destined to develop recurrent disease. In order to minimize morbidity in patients with invasive disease, bladder-sparing techniques using radiotherapy alone, or with chemotherapy, have been investigated. While it is clear that durable complete remission can be achieved in some patients, the results to date require additional follow-up to determine the optimal cohort of patients destined to benefit from this approach. It is hoped that ongoing prospective trials will delineate this population.

UR - http://www.scopus.com/inward/record.url?scp=0026670398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026670398&partnerID=8YFLogxK

M3 - Article

C2 - 1509286

AN - SCOPUS:0026670398

VL - 19

SP - 92

EP - 95

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 11

ER -